Contacts
Info
A collection of stories and insights on matters of discovery that advance life sciences. Brought to you by the curious people at Cytiva.
24 OCT 2024 · Join us as Dr. Aravind Asokan from Duke University explores cutting-edge technologies revolutionizing advanced therapies, including CRISPR, mRNA, viral vectors, and cell therapies. He shares key lessons from past challenges, discusses scalability, product quality, and how integrating various therapeutic approaches is shaping the future of disease treatment. This episode covers exciting advancements in AAV with CRISPR, CAR T cell therapy, circular RNA, and virus-like particles (VLPs).
Show notes: Asokan A, et al. ‘An evolved AAV variant enables efficient genetic engineering of murine T cells’. Cell. 2023 Jan 19;186(2):446-460. https://doi.org/10.1016/j.cell.2022.12.022
10 OCT 2024 · Dive into the fascinating world of virology as we welcome Nobel Prize-winning virologist Dr. Michael Houghton on this episode of Discovery Matters. We explore Dr. Houghton's groundbreaking work in identifying the hepatitis C virus (HCV) and his enduring quest to combat this global health threat. From the monumental discovery of HCV in 1982 to the revolutionary diagnostic tests that nearly eradicated transfusion-related hepatitis C by the mid-1990s, Dr. Houghton provides an engaging and insightful journey through decades of scientific innovation. Show notes
- Richard D Roberts, Patrick C Kyllonen, ‘Morningness–eveningness and intelligence: early to bed, early to rise will likely make you anything but wise!’ Personality and Individual Differences, Volume 27, Issue 6, 1999. https://doi.org/10.1016/S0191-8869(99)00054-9.
- Taquet, MaximeLone, Nazir et al. ‘Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK.’ The Lancet Psychiatry, Volume 11, Issue 9. https://doi.org/10.1016/S2215-0366(24)00214-1
26 SEP 2024 · Eco-design, collaboration, circular economy. These are the bywords of sustainability in biopharma. Join Ryan Walker, Senior Director of Sustainability at Cytiva, and Aude Arkham, Global Head of Eco Design and Circular Economy at Sanofi, as they explore how eco-design and circular economy initiatives are shaping the future of healthcare. We delve into challenges, achievements, and the transformational potential of sustainability efforts within biopharma. From Sanofi’s life cycle assessments to industry-wide data difficulties, this episode navigates the complex landscape of creating greener solutions without compromising innovation and compliance.
5 SEP 2024 · In this episode of "Discovery Matters," we dive into the powerful intersection of big data and artificial intelligence. Joined by Matej Macak, a partner from McKinsey, we unravel how AI and machine learning are revolutionizing our approach to finding new, effective medications. With Tom Yankeelov, Professor of Biomedical Engineering, Diagnostic Medicine, Oncology at the University of Texas for Austin, we'll explore the "problem of averages" and much more.
22 AUG 2024 · What does 'the body as a bioreactor' mean? In this discussion how scientists use the body's machinery to produce therapeutic proteins. Scott Ripley, General Manager of Nucleic Acids at Cytiva, explains that traditional bioprocessing uses external bioreactors, while the new approach leverages the body's natural processes. This method offers benefits like longer protein half-life and the ability to express multiple proteins simultaneously. Justin Eyquem, assistant professor at University of California San Francisco, discusses the potential of in vivo CAR T cell therapy, which could simplify manufacturing and reduce costs. Both approaches face challenges in quality assurance and regulatory approval but hold promise for personalized and more effective treatments.
8 AUG 2024 · We're diving into advanced therapies with industry leaders. Emmanuel Abate, President of Genomic Medicine at Cytiva discussed the strategies to accelerate clinical work and reduce costs. Nathaniel Wang, CEO and Co-Founder of Replicate Bioscience highlighted their ground breaking self-replicating RNA technology, showcasing impressive clinical results for a rabies vaccine. Both experts emphasized the momentum in biotech, the potential of AI in advancing science, and the importance of making innovative therapies accessible globally. Stay tuned for these insights. Show notes
- https://www.science.org/content/article/beneath-everest-lone-caretaker-struggles-keep-one-world-s-highest-laboratories-alive#:~:text=LOBUCHE%2C%20NEPAL%E2%80%94Here%20on%20the,once%20again%20hum%20with%20activity.
- https://doi.org/10.1038/s41467-024-48153-z
Keywords: vaccines, advanced therapies, mRNA, manufacturing, technology, patients, innovation, new modalities.
21 MAY 2024 · From gene and cell therapies, to the use of CRISPR and other precision engineering technologies, this episode dives into the opportunities and challenges of the emerging field of advanced therapies. On Discovery Matters this week, Dodi and Conor are joined by Daria Donati, Chief Scientific Officer of Genomic Medicine at Cytiva, as well as Jen Moody, Vice President of External Innovation of Genomic Medicines at Danaher, to discuss the science, progress, and potential of advanced therapeutics. Demaris Mills, Group Executive of Genomic Medicines at IDT, and experts Fyodor Urnov, Professor of Molecular and Cell Biology at the University of California, Berkeley, and the Director of Technology & Translation at the Innovative Genomics Institute, cover the technologies used in gene and cell therapies as well as CRISPR to deliver powerful and precise treatments aiming for a healthier future.
30 APR 2024 · Can you tell the difference between a human and AI? Of course you can…right? We challenge Conor and Dodi to tell the difference between Conor and Conor BOT all while uncovering how AI is transforming the life sciences. Uncover how AI is transforming the life sciences. Together with an AI-bot the pair explore the potential applications of AI in drug discovery, personalizing medical treatments, protein folding, and more. They also consider the ethical considerations required when developing AI models, as well as the need for emotional intelligence in AI systems. Keywords: AI, ethical dilemma, bias, misinformation, datasets, diagnostics, drug discovery, healthcare.
11 APR 2024 · Let's explore the remarkable colour-changing abilities of cephalopods. Joined by Dan Wilson from the Costas Research Institute at Northeastern University, the team dive into the fascinating research behind the development of paints that respond to environmental stimuli, such as sunlight. They also discuss titanium dioxide and how it acts as a facilitator of the colour-changing process. Professor Alon Gorodetsky, Associate Professor of Chemical and Biomolecular Engineering at the University of California, Irvine, talks about his research on developing energy-responsive dyes to mimic the features of octopi. Discover the potential applications of these dyes from diagnostics to resource-constrained initiatives, and more. Listen in and discover this remarkable evolutionary adaptation and the incredible ingenuity of cephalopods.
28 MAR 2024 · In this episode of Discovery Matters, hosts Dodi and Conor explore how synthetic biology can lead to transformative breakthroughs when it comes to dealing with global health problems. Through their conversation with Justin Vigar, a PhD student in Dr. Keith Pardee's lab at the University of Toronto in Canada, we learn how his paper-based diagnostic tool has the potential to provide faster, more cost-efficient, and accessible diagnostics for underserved locations. This is complemented by Amir Pandi and Tobi Erb's discussion of using AI and synthetic biology to develop new antimicrobial peptides. Show notes •https://www.utoronto.ca/news/u-t-phd-student-uses-synthetic-biology-create-low-cost-diagnostic-tools. •Pandi, A., Adam, D., Zare, A. et al. Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides. Nat Commun 14, 7197 (2023). https://doi.org/10.1038/s41467-023-42434-9 •Khalek IS, et al. Synthetic development of a broadly neutralizing antibody against snake venom long-chain α-neurotoxins. Sci Transl Med. 2024 Feb 21;16(735). https://doi.org/10.1126/scitranslmed.adk1867 •Josh A Goldstein, Jason Chao, Shelby Grossman, Alex Stamos, Michael Tomz, How persuasive is AI-generated propaganda?, PNAS Nexus, Volume 3, Issue 2, February 2024. https://doi.org/10.1093/pnasnexus/pgae034
A collection of stories and insights on matters of discovery that advance life sciences. Brought to you by the curious people at Cytiva.
Information
| Author | Bethany Grace Armitt-Brewster |
| Organization | Bethany Grace Armitt-Brewster |
| Categories | Life Sciences |
| Website | www.spreaker.com |
| - |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
